313 related articles for article (PubMed ID: 12027418)
1. The flavonoid Kaempferol suppresses the graft-versus-host reaction by inhibiting type 1 cytokine production and CD8+ T cell engraftment.
Okamoto I; Iwaki K; Koya-Miyata S; Tanimoto T; Kohno K; Ikeda M; Kurimoto M
Clin Immunol; 2002 May; 103(2):132-44. PubMed ID: 12027418
[TBL] [Abstract][Full Text] [Related]
2. Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease. Regulatory role of donor CD8+ T cells.
Rus V; Svetic A; Nguyen P; Gause WC; Via CS
J Immunol; 1995 Sep; 155(5):2396-406. PubMed ID: 7650373
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Vallera DA
J Immunol; 1998 Jun; 160(11):5355-65. PubMed ID: 9605135
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing IL-12 during induction of murine acute graft-versus-host disease polarizes the cytokine profile toward a Th2-type alloimmune response and confers long term protection from disease.
Williamson E; Garside P; Bradley JA; More IA; Mowat AM
J Immunol; 1997 Aug; 159(3):1208-15. PubMed ID: 9233615
[TBL] [Abstract][Full Text] [Related]
5. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease.
Krenger W; Snyder KM; Byon JC; Falzarano G; Ferrara JL
J Immunol; 1995 Jul; 155(2):585-93. PubMed ID: 7608537
[TBL] [Abstract][Full Text] [Related]
6. Allospecific CD4+, Th1/Th2 and CD8+, Tc1/Tc2 populations in murine GVL: type I cells generate GVL and type II cells abrogate GVL.
Fowler DH; Breglio J; Nagel G; Hirose C; Gress RE
Biol Blood Marrow Transplant; 1996 Oct; 2(3):118-25. PubMed ID: 9199754
[TBL] [Abstract][Full Text] [Related]
7. IL-12 stimulates the development of acute graft-versus-host disease in mice that normally would develop chronic, autoimmune graft-versus-host disease.
Via CS; Rus V; Gately MK; Finkelman FD
J Immunol; 1994 Nov; 153(9):4040-7. PubMed ID: 7930611
[TBL] [Abstract][Full Text] [Related]
8. Prevention of graft-versus-host disease by a novel immunosuppressant, (5R)-5-hydroxytriptolide (LLDT-8), through expansion of regulatory T cells.
Tang W; Yang Y; Zhang F; Li YC; Zhou R; Wang JX; Zhu YN; Li XY; Yang YF; Zuo JP
Int Immunopharmacol; 2005 Dec; 5(13-14):1904-13. PubMed ID: 16275625
[TBL] [Abstract][Full Text] [Related]
9. In vivo depletion of CD8+ T cells results in Th2 cytokine production and alternate mechanisms of allograft rejection.
Chan SY; DeBruyne LA; Goodman RE; Eichwald EJ; Bishop DK
Transplantation; 1995 Apr; 59(8):1155-61. PubMed ID: 7732563
[TBL] [Abstract][Full Text] [Related]
10. Cells of Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host reaction. Regulation of cytokines and CD8+ lymphoid engraftment.
Fowler DH; Kurasawa K; Husebekk A; Cohen PA; Gress RE
J Immunol; 1994 Feb; 152(3):1004-13. PubMed ID: 7905495
[TBL] [Abstract][Full Text] [Related]
11. Roquinimex-mediated protection effect on the development of chronic graft-versus-host disease in mice is associated with induction of Th1 cytokine production and inhibition of proinflammatory cytokine production.
Xiao ZY; Zhou WX; Zhang YX; Cheng JP; He JF; Yang RF; Yun LH
Life Sci; 2007 Oct; 81(19-20):1403-10. PubMed ID: 17950363
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy.
Jung U; Foley JE; Erdmann AA; Toda Y; Borenstein T; Mariotti J; Fowler DH
Biol Blood Marrow Transplant; 2006 Sep; 12(9):905-18. PubMed ID: 16920556
[TBL] [Abstract][Full Text] [Related]
13. [A role for T-helper type 1 and type 2 cytokines in the pathogenesis of various human diseases].
Kasakura S
Rinsho Byori; 1998 Sep; 46(9):915-21. PubMed ID: 9800477
[TBL] [Abstract][Full Text] [Related]
14. Development of CD8+ effector T cells is differentially regulated by IL-18 and IL-12.
Okamoto I; Kohno K; Tanimoto T; Ikegami H; Kurimoto M
J Immunol; 1999 Mar; 162(6):3202-11. PubMed ID: 10092771
[TBL] [Abstract][Full Text] [Related]
15. Adoptive transfer of small numbers of DX5+ cells alleviates graft-versus-host disease in a murine model of semiallogeneic bone marrow transplantation: a potential role for NKT lymphocytes.
Margalit M; Ilan Y; Ohana M; Safadi R; Alper R; Sherman Y; Doviner V; Rabbani E; Engelhardt D; Nagler A
Bone Marrow Transplant; 2005 Jan; 35(2):191-7. PubMed ID: 15558045
[TBL] [Abstract][Full Text] [Related]
16. CD4 Th2 cells do not functionally suppress CTL generation in neonatal tolerant mice.
Gao Q; Chen N; Field EH
Transplantation; 1995 Dec; 60(11):1260-8. PubMed ID: 8525520
[TBL] [Abstract][Full Text] [Related]
17. Co-stimulated/Tc2 cells abrogate murine marrow graft rejection.
Erdmann AA; Jung U; Foley JE; Toda Y; Fowler DH
Biol Blood Marrow Transplant; 2004 Sep; 10(9):604-13. PubMed ID: 15319772
[TBL] [Abstract][Full Text] [Related]
18. Intervention of MAdCAM-1 or fractalkine alleviates graft-versus-host reaction associated intestinal injury while preserving graft-versus-tumor effects.
Ueha S; Murai M; Yoneyama H; Kitabatake M; Imai T; Shimaoka T; Yonehara S; Ishikawa S; Matsushima K
J Leukoc Biol; 2007 Jan; 81(1):176-85. PubMed ID: 17053165
[TBL] [Abstract][Full Text] [Related]
19. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation.
Fowler DH; Odom J; Steinberg SM; Chow CK; Foley J; Kogan Y; Hou J; Gea-Banacloche J; Sportes C; Pavletic S; Leitman S; Read EJ; Carter C; Kolstad A; Fox R; Beatty GL; Vonderheide RH; Levine BL; June CH; Gress RE; Bishop MR
Biol Blood Marrow Transplant; 2006 Nov; 12(11):1150-60. PubMed ID: 17085308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
